AlbACS-1Pro
Albumin Utilization for Intravascular Volume Replacement in Adult Cardiac Surgical Patients : A Multicentre Prospective Cohort Study
Sponsor study identifier
observational
104
1 country
2
Study Start
June 11, 2024
Actual (reported)Primary Completion
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of our proposed multicentre prospective cohort study is to characterize perioperative usage patterns of crystalloids and albumin, as well as key patient outcomes, in cardiac surgical patients. Results obtained from this observational study will be combined with the results of other studies to clarify the optimal role of albumin and other blood products in the perioperative management of cardiac surgical patients. This study will also address numerous other knowledge gaps in the area of perioperative blood product management and fluid administration in cardiac surgery and define a collaborative group to support future research in this field.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 21, 2024
Actual (reported)May 2, 2024
Actual (reported)June 11, 2024
Actual (reported)December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Albumin (g/L)
Type, dose and timing of administration, the setting in which it was ordered, indication for use, and the type of provider responsible for the patient at administration (surgeon, anesthesiologist, intensivist, nurse practitioner).
On CPB, in the operating room but not during CPB, in the ICU, on the ward to post operative day 28
Antithrombin III (g/L)
Measured in g/L
On CPB, in the operating room but not during CPB, in the ICU, on the ward to post operative day 28
Crystalloid
and others), as well as the setting of administration will be recorded.
On CPB, in the operating room but not during CPB, in the ICU, on the ward to post operative day 28.
All consenting adults undergoing cardiac surgery at Toronto General Hospital and Kingston Health Sciences Centre.
The study will include 100 adult (≥18 years old) patients who are undergoing major cardiac surgery. All adult (≥18 years old) patients who are undergone cardiac surgery (with or without the use of cardio-pulmonary bypass) will be eligible. There are no specific exclusion criteria, except lack of consent.
Kingston Health Sciences Centre
Kingston, Ontario, K7L 3N6, Canada
Toronto General Hospital - University Health Network
Toronto, Ontario, M5G 2C4, Canada
Blood sample
Keyvan Karkouti, MD MSc FRCPC
Toronto General Hospital - University Health Network
104 participants (actual enrollment reported by the registry).
First Submitted
February 21, 2024
First Posted
May 2, 2024
Study Start
June 11, 2024
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 25, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: